Trials / Completed
CompletedNCT02359292
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers
Cross-over Clinical Pharmacology Study, to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination Across Two Different Dose Strengths, Administered With and Without Activated Charcoal, in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Chiesi Farmaceutici S.p.A. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The study is performed to evaluate the total systemic exposure and lung bioavailability of CHF 5993 pMDI combination, in healthy volunteers subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CHF 5993 HS 200/6/25 pMDI | |
| DRUG | CHF 5993 MS 100/6/25 pMDI | |
| DRUG | CHF 5993 HS 200/6/25 pMDI + Charcoal Block | |
| DRUG | CHF 5993 MS 100/6/25 pMDI + Charcoal Block | |
| DRUG | Placebo pMDI |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-04-01
- Completion
- 2015-07-01
- First posted
- 2015-02-10
- Last updated
- 2021-07-02
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02359292. Inclusion in this directory is not an endorsement.